Recombinant alkaline phosphatases are becoming promising protein therapeutics to prevent skeletal mineralization defects, inflammatory bowel diseases, and treat acute kidney injury. By substituting the flexible crown domain of human intestinal alkaline phosphatase (IAP) with that of the human placental isozyme (PLAP) we generated a chimeric enzyme (ChimAP) that retains the structural folding of IAP, but displays greatly increased stability, active site Zn2+ binding, increased transphosphorylation, a higher turnover number and narrower substrate specificity, with comparable selectivity for bacterial lipopolysaccharide (LPS), than the parent IAP isozyme. ChimAP shows promise as a protein therapeutic for indications such as inflammatory bowel diseases, gut dysbioses and acute kidney injury.
Citation: Kiffer-Moreira T, Sheen CR, Gasque KCdS, Bolean M, Ciancaglini P, van Elsas A, et al. (2014) Catalytic Signature of a Heat-Stable, Chimeric Human Alkaline Phosphatase with Therapeutic Potential. PLoS ONE 9(2): e89374. doi:10.1371/journal.pone.0089374
Editor: Panagiotis A. Tsonis, University of Dayton, United States of America
Received: December 11, 2013; Accepted: January 17, 2014; Published: February 24, 2014
Copyright: © 2014 Kiffer-Moreira et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by grant R01 DE12889 from the National Institutes of Health, USA, and a small grant from AM Pharma. The funder provided support in the form of salaries for authors [TKM, KCDSG], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Dr. Andrea van Elsas, co-author of this paper, is VP of Research of AM Pharma, a company that is now manufacturing the ChimAP described in this paper and conducting clinical trials with this novel protein therapeutic. This study was funded in part by AM Pharma. The authors have the following patent/patent applications relating to material pertinent to this article: Australia: 2008244716, China: ZL 2008 80017810.0, Japan: 5320387, US: 8,557,545, Canada: 2,685,405, Europe: 08741670.7, all entitled: “Modified Phosphatases”. The authors have declared their adherence to all the PLoS ONE policies on sharing data and materials.
Recombinant alkaline phosphatases (APs) (EC 184.108.40.206) show promise as therapeutic drugs for a variety of conditions ranging from soft-bone diseases such as hypophosphatasia (HPP) , inflammatory bowel diseases –, gut dysbiosis ,  and acute kidney injury –. Enzyme stability and substrate specificity are important parameters influencing the choice of isozyme to be used for a particular clinical indication. This paper describes the rationale for the construction of a chimeric enzyme (ChimAP) and its kinetic and biophysical properties.
APs are encoded by a multigene family  that in humans comprises four loci: ALPL encodes an enzyme expressed primarily in bone, liver and kidney, referred to as tissue-nonspecific AP (TNAP). The other three loci are highly homologous and are expressed in a tissue-specific manner. These genes, ALPI, ALPP and ALPPL2, encode intestinal AP (IAP), placental AP (PLAP) and placental-like or germ cell AP (GCAP), respectively. The known functions of these isozymes are quite different and relate to their substrate specificity . Mutations in the human ALPL gene (Alpl in mice), cause hypophosphatasia (HPP), which is characterized by severe rickets, seizures and often perinatal death. The defects in HPP are caused by inadequate hydrolyses of the mineralization inhibitor  inorganic pyrophosphate (PPi) and pyridoxal-5′phosphate (PLP, a major isomer of vitamin B6), which are two physiological substrates of TNAP , . In collaboration with Enobia Pharma (now Alexion Pharmaceuticals), our group developed the first therapeutic AP, a bone mineral-targeting recombinant TNAP (Asfotase alfa) that prevented seizures and all the skeletal and dental manifestations of HPP by normalizing PPi and PLP metabolism , –. Clinical trials using asfotase alfa in patients with life-threatening HPP have shown remarkable results  (Clinicaltrials.gov Identifier NCT00744042) and are now continuing with adolescents and adults with HPP (ClinicalTrials.gov Identifiers: NCT00952484 and NCT01163149).
IAP has many interrelated functions in the gut. IAP participates in a rate-limiting step during fatty acid absorption with IAP knockout mice becoming obese  and developing metabolic syndrome under a high fat diet . Importantly, IAP is a mucosal defense factor  maintained by enteral nutrition  that contributes to the establishment of the normal homeostatic gut microbiota , . Furthermore, administration of bovine IAP prevents pathophysiological changes in mouse models of chronic colitis  by inhibiting pro-inflammatory pathways mediated by LPS, a gram negative bacterial endotoxin , and UDP  and preventing the development of metabolic syndrome in IAP knockout mice .
Here, we have developed a human recombinant AP that displays enhanced stability and good selectivity for LPS, the main pathophysiological substrate involved in acute kidney injury, inflammatory bowel diseases and gut dysbiosis. Our earlier studies on the structure of PLAP revealed an active site, with two active Zn2+ residues (Zn1 and Zn2) and a third metal ion site, occupied by Mg2+. While Zn2 is buried within the molecule, Zn1 is easily accessible and its reactivity can be modulated –. Both Zn1 and Zn2 coordinate with highly conserved amino acids  and our mutagenesis studies uncovered a major role for residue E429 in determining the affinity of Zn1, and thus the stability and catalytic properties of the PLAP active site as well as determining the overall thermal properties of the enzyme , –. We predicted that introducing the well-characterized crown domain of PLAP, harboring the critical E429 residue, into the IAP structure would improve enzyme stability while preserving or enhancing catalytic function of the resulting chimeric enzyme. Here, we show that ChimAP displays greatly increased heat stability, increased Zn2+ binding affinity, increased transphosphorylation, a higher turnover number and narrower substrate specificity, with comparable selectivity for bacterial LPS, than the parent IAP isozyme. Clinical trials using ChimAP have been initiated with the goal to treat patients with acute kidney injury (http://www.am-pharma.com/blog/2013/09/am-pharma-returns-to-clinic-with-phase-i-trial-of-new-recombinant-human-alkaline-phosphatase).
3D model of ChimAP
Figure 1A schematically illustrates where the PLAP amino acid segment was substituted into IAP (residues 360-430) to construct the chimeric enzyme ChimAP. The 3D positioning of the crown domain ,  of ChimAP in the structural model of IAP illustrates how this compactly folded domain is a determinant of the IAP active site environment (Figure 1B, C). Figure 2A shows the complete sequence alignment of human IAP and ChimAP. Only 16 crown domain residues differ between them.
(A) Schematic representation of the fusion of the first 359 amino acids of the mature human IAP structure to residues 360–430 of the mature human PLAP sequence followed by residues 431–484 of the human mature IAP sequence. (B) 3D representation of the ChimAP structure based on homology to human PLAP, visualized and analyzed using Chimera v1.7 and Swiss-PdbViewer. (C) Top view of the ChimAP structure, indicating the active site serine. Active site metal ions are displayed. The crown domain is represented in red.
(A) Protein sequence alignment showing IAP and ChimAP sequence conservation. Substitutions are those introduced by replacement with the PLAP crown domain. (B) Western blot analysis showing that all four enzymes were secreted into the culture medium.
Production of FLAG-tagged enzymes
To compare the kinetic properties of IAP, PLAP and ChimAP with TNAP, and to directly compare ChimAP with its parent enzymes, we added a FLAG-tag sequence to the IAP and ChimAP cDNAs, as we did previously to comparatively study PLAP and TNAP , . The cDNAs were expressed in COS-1 cells and culture supernatant containing secreted enzymes was recovered. Successful expression and recovery were confirmed by anti-FLAG antibody western blot analysis (Figure 2B); all four monomers have comparable molecular masses of approximately 70 kDa.
Active site stability
The flexible top loop, which is part of the crown domain, plays a major role in the AP structure-function relationship , . To test our hypothesis that introducing the PLAP crown domain in to IAP would affect enzyme stability and kinetics of ChimAP, we first determined the rate of the catalytic Zn1 ion dissociation at physiological pH, in the presence of 250 µM EDTA, to preclude dissociated Zn2+ from rebinding. Figure 3 shows that Zn1 ion dissociation  is a first order process, with half-lives of 20 min (IAP), 180 min (ChimAP) and 360 min (PLAP), corresponding to dissociation rate constants of 58×10−5 s−1, 6.4×10−5 s−1 and 3.2×10−5 s−1, respectively. This data shows that Zn1 readily dissociates from IAP, but is almost as tightly bound to its coordinating amino acids in ChimAP as in PLAP.
The slopes between these lines were highly significantly different (p<0.0001).
Directly adding the active site metal chelator agent Chelex to all three enzymes removed Zn2+ with similar inactivation kinetics (not shown). During this time frame, enzymes were quickly regenerated upon adding Zn2+, which dose-dependently reconstituted the active site in IAP, PLAP, the highly active bovine IAP (bIAP) II , and ChimAP, reaching steady-state enzyme activity in a few minutes (Figure 4). Zn2+ reconstitution occurred between 0.1–1 µM Zn2+, with the exception of IAP where an additional sharp rise of enzyme activity occurred between 5–20 µM Zn2+. These findings suggest similar association rates constants in all cases, i.e. full active site access, even though the profile for IAP suggests additional conformational changes occurring in demetalated IAP . To minimize protein monomerization and incomplete recovery during IAP remetalation, reconstitution was initiated before full enzyme inactivation was achieved, explaining the residual activity at 0.01 µM Zn2+ in Figure 4. Absence of Mg2+ can explain the drop in enzyme activity at [Zn2+]>10 µM, because Zn2+ binding to the Mg2+ site inhibits PLAP activity .
Kinetics parameters with standard pNPP substrate at pH 9.8 and 7.4
The baseline kinetic characterization of ChimAP at alkaline pH in a transphosphorylating buffer is shown in Figure 5, with pNPP as a substrate. This figure illustrates that the determination of catalytic AP properties at alkaline pH bears little relevance to their application at physiological pH. Table 1 summarizes the kinetic constants for the substrate pNPP at both pHs for all enzymes. At pH 9.8 IAP, TNAP and ChimAP have comparable catalytic efficiency. However, closer analysis shows that Km and kcat are about five-fold higher for ChimAP than for IAP. Interestingly, despite its low Km at pH 7.4, ChimAP has kcat values that are higher than IAP, and almost as high as the highly active bIAP II (123 s−1). Overall, the catalytic efficiency of ChimAP was the highest at pH 7.4 (Table 1), justifying further analysis of physiological substrates at this pH, using pNPP as a reference.
Kinetics parameters with physiological substrates
The phosphohydrolase properties of ChimAP were investigated for physiological substrates implicated in bone metabolism, inflammation and seizures, specifically the mineralization inhibitor PPi, the nucleotides ATP, ADP and AMP, LPS and the vitamin B6 vitamer PLP. Figures 6–9 show relative binding saturation for all enzymes, using ATP, PPi, LPS and PLP as substrates, which illustrates that LPS and PLP are good substrates for ChimAP. These findings are summarized in Table 2, including data for ADP and AMP. The data reveal comparable to superior catalytic efficiencies for IAP and TNAP, consistent with the role of the latter in bone metabolism, where it is a potent pyrophosphatase . Overall, the kcat constants were comparable to those measured for pNPP at pH 7.4 following the same methodology. Small differences were found for all three nucleotides, but most striking was that the Km of ChimAP is especially high with PPi, and lower with ATP as a substrate. At the same time, kcat for PPi is low, categorizing ChimAP, together with PLAP, as an enzyme with a poor catalytic efficiency for PPi hydrolysis. Importantly, at physiological pH with all other substrates, ChimAP displayed equal or greater kcat constants than IAP (Table 2).
Plots are representative of three separate experiments.
Plots are representative of three different experiments.
Plots are representative of three different experiments.
Plots are representative of three different experiments.
Integrated inhibition experiments were carried out, in which ATP, PPi and LPS were allowed to compete with a fixed concentration of pNPP (0.1 mM). Figure 10 illustrates that both ATP and PPi most easily displace pNPP from TNAP and LPS displaces pNPP most easily from IAP, at pH 7.4. Although TNAP and ChimAP have a comparable Km for pNPP, ATP and PPi displace pNPP from ChimAP less efficiently, consistent with the highest Kms of ChimAP for these substrates. Likewise, LPS displaces pNPP from ChimAP with the lowest efficiency. Active site catalysis was also probed using the established uncompetitive active site inhibitors L-Phe and L-hArg (Figure 11). Table 3 shows that the inhibition constant for L-Phe is about six-fold higher for ChimAP than for IAP. Also, ChimAP was less inhibited by L-hArg than PLAP and IAP.
The lines represent fitted inhibition curves. Inset: respective double-reciprocal plots of FLAG-tagged PLAP, IAP and ChimAP activity in the presence or absence of the indicated concentrations of L-Phe.
The impact of the crown domain exchange on the overall stability of the enzyme was investigated via unfolding in guanidinium hydrochloride and by heat inactivation studies. Figure 12A shows ChimAP denaturation as a function of time, when incubated in 3.8 M GndCl, first slowly but then exponentially. The slopes of the denaturation rates were highly statistically different (p<0.0001), but the value for the fractional disappearance rate per minute of ChimAP activity (9.5±0.24×10−3) was considerably closer to the inactivation rate of IAP (12.2±0.97×10−3) than to that of PLAP (21.5±0.59×10−3) (Table 4). Consistent with the 95% sequence homology between IAP and ChimAP, these findings confirm that the overall structure of ChimAP resembles that of IAP. PLAP is extremely resistant to heat inactivation at high temperatures (Figure 12B) and showed the highest resistance to heat of the APs studied (Table 4). In contrast, IAP and TNAP are relatively heat labile. ChimAP displays strong heat stability, almost comparable to that of PLAP. Consistent with the existence of a stable Zn environment in the active site of ChimAP (Figure 3), these findings indicate that the crown domain enhances stability to the active site region of ChimAP. Detailed inactivation kinetics at 65°C confirmed that IAP and TNAP were inactivated rapidly, following first order kinetics, whereas the slow loss of ChimAP activity matched the extreme heat stability of PLAP (Figure 12C, Table 4).
(A) Plot of residual enzyme activity in the exponential phase of enzyme inactivation for FLAG-tagged PLAP, IAP, ChimAP and TNAP, showing the effect of the denaturing agent guanidinium hydrochloride. (B, C). Lines in B and C are representative of three separate experiments. Heat inactivation of FLAG-tagged enzymes PLAP, IAP, ChimAP and TNAP. The enzymes were incubated for 10 min at different temperatures (25–100°C) (B) or for different time intervals at 65°C (C).
Previous work in our laboratory has demonstrated the crucial importance of the flexible surface loop of mammalian APs in determining isozyme-specific properties in this enzyme family . Replacement of the flexible surface loop of TNAP with that of PLAP conferred heat stability properties and stabilized uncompetitive inhibitors in the active site of TNAP , , , _ENREF_26_ENREF_27. Furthermore, the stability of the catalytic metal ions in PLAP was lost upon introduction of a E429G substitution in that loop . In the current paper we have constructed the chimeric ChimAP recombinant enzyme with improved stability and kinetic properties towards physiological substrates. Replacing the entire crown domain of human IAP with the equivalent residues of PLAP (16 amino acid substitutions) conferred greatly enhanced heat and Zn stability to ChimAP, approaching that of PLAP, while also maintaining and enhancing the substrate specificity of ChimAP for the physiologically relevant substrate LPS. The substituted crown domain markedly influenced the active site localization of Zn2+, in turn enhancing enzyme activity. In addition to the amino acid residues coordinating Zn2+ , the stability of the Zn2+ ions is lost by mutation of E429G in PLAP . Consistent with those findings, the increase in Zn2+ stability observed between IAP and ChimAP is explained by the presence of E429 in ChimAP (Figure 13).
IAP, PLAP and ChimAP are shown in orange, white and blue, respectively.
The presence of E429 is also the possible explanation for the kinetic behavior of ChimAP with pNPP at pH 9.8 and with physiological substrates at physiological pH. Enzyme catalysis by AP can be represented schematically as follows:where E is enzyme, S is substrate and P is product, with kcat = k2/(1+k2/k3) and Km = (k−1+k2)/k1(1+k2/k3). Furthermore, the catalytic efficiency corresponds to kcat/Km = k1/(1+k−1/k2) and the inhibition constant for uncompetitive inhibition Ki = KEPI(1+k3/k2).
One concern that we had was that the PLAP crown domain residue E429 would cause active site hindrance in ChimAP, and be the cause of the high Km for pNPP measured at pH 9.8. Yet, the kcat was similarly increased in these conditions, hence resulting in a comparable kcat/Km ratio as for IAP. Since both Km and kcat/Km depend on the active site entrance constant k1, steric hindrance can be excluded, because it would have affected both parameters. Since in the overall reaction k−1<<k2, this conclusion suggested the rate of phosphorylation of the active site serine residue (k2) or the rate of transphosphorylation onto DEA (k3) to be affected in ChimAP. A rise in k2 can be excluded, because it would also lead to a lower Ki (at constant KEPI in the absence of active site hindrance). Therefore, our findings are compatible with an increase in k3, explaining a similar rise in kcat and Km and a parallel rise of Ki. In other words, the increased Zn stability results in more efficient intramolecular hydrolysis of the phospho-enzyme complex and transfer of the hydrolyzed Pi group to the transphosphorylation buffer DEA. In contrast, at pH 7.4, transphosphorylation is virtually absent and the same relationship no longer applies. Moreover, with various physiological substrates, no single trend was observed, i.e. kcat and Km did not consistently change in the same direction.
At pH 7.4, ChimAP is characterized by three unique properties: a) Km values are higher than for IAP with all substrates, b) kcat values are also slightly higher, except with PPi as a substrate, and c) ChimAP shows selectivity for some substrates. Overall, catalytic efficiencies were comparable for ChimAP and IAP, but in some cases were lower than for TNAP. PPi appeared to be a poor substrate (high Km and low kcat) for ChimAP resulting in a low catalytic efficiency. It is clear from the rise in Km and the drop in kcat that, in addition to an effect on k2, k1 is also lowered in ChimAP when PPi is the substrate, as compared to IAP. It is noteworthy that PLAP is a poor enzyme with all the the presently studied physiological substrates; it had the lowest catalytic rate constants for all substrates. The dual negative PLAP-like amino acid replacements S428D and S429E in ChimAP may explain this finding, as PLAP also hydrolyses the highly negatively charged PPi poorly. We surmise that the S429E substitution in the vicinity of the ChimAP active site reduces active site entrance of strongly negatively charged substrates such as ATP, and even more so for the smaller but more densely negative PPi. However, at physiologically low substrate concentrations (i.e. below the respective Km), ChimAP can hydrolyze some substrates at least as effectively as IAP.
Our studies reveal a relative preference of IAP and ChimAP for the physiological substrates LPS>PLP>ATP>PPi, while the reverse is true for TNAP, with a preference order of PPi>PLP = ATP>LPS. This substrate preference correlates well with the known biological function of the native isozymes, where IAP is involved in maintaining gut mucosal barrier function via LPS detoxification. Here, we have not attempted to compare different types of LPS, as the main objective has been to engineer the enzyme to improve its biophysical properties and narrow down specificity. However, we previously reported that bIAP , murine TNAP and IAP  are able to dephosphorylate E.coli LPS O55:B5. Also, human PLAP is able to dephosphorylate LPS (Re595) from S. minnesota as well as E. coli LPS O55:B5 . Thus, it is likely that ChimAP will be active towards LPS produced by a wide number of bacteria. Neither have we systematically compared LPS and monophosphoryl-lipid A (MPLA) as substrates for ChimAP. However, Bentala et al  demonstrated that LPS, but not MPLA, from S. minnesota Re595, is a good substrate for human PLAP. Given that ChimAP has acquired many biophysical characteristics of PLAP, it is likely that the discrimination between di- and monophosphorylated lipid A will also be displayed by ChimAP.
TNAP is required during the physiological mineralization of skeletal and dental tissues via its ability to control the Pi/PPi ratio with its pyrophosphatase function , . TNAP is also required in the metabolism of PLP, the most important vitamin B6 vitamer, which is an essential cofactor for neurotransmitter synthesis ,  and also in establishing an appropriate ATP/adenosine ratio for nociception in the dorsal root ganglia  and in neonatal blood . PLAP appears relatively inefficient in hydrolyzing most of these physiological substrates, and it is still unclear what its biological role is. However, the fact that large amounts of PLAP are expressed in the human placenta from the second trimester of pregnancy until term may compensate for the suboptimal kinetic properties of this isozyme . In contrast, the highly specific presence of IAP in the brush border of the S3 segment of the human renal proximal tubule  has been an enigma for over two decades. In view of the high IAP catalytic efficiency shown in the present study, it seems logical that the highly vulnerable S3 segment of the proximal tubule expresses an enzyme that hydrolyses phosphorylated compounds, such as LPS and ATP, very efficiently to avoid cellular damage upon re-absorption of such substrates. The kinetic observations in this study parallel what we know about the evolutionary relationship between these isozymes, with ALPL (encoding human TNAP) being the most ancestral of the AP genes, followed by a clustering of all the intestinal isozymes in all species studied (ALPI encoding human IAP) with functions clearly unrelated to those of TNAP. The latest evolutionary members of this family of isozymes, PLAP (ALPP) and the closely related GCAP (ALPPL2), have unknown biological functions and show a marked degree of genetic variability, consistent with their late appearance during evolution .
In conclusion, ChimAP is an enzyme with increased stability, increased Zn2+ binding affinity, increased transphosphorylation, a higher turnover number and narrower substrate specificity with selectivity for bacterial LPS, compared to the parent IAP isozyme. In fact, ChimAP displays turnover rates for various pathophysiologically relevant substrates with values that compare well with the rates displayed by the AP isozyme with the highest turnover numbers known to-date, that of the Bos taurus bIAP II isozyme . The increased stability of ChimAP should facilitate the development of formulations suitable not only for intravenous administration, as may be required for the treatment of acute kidney injury, but also for oral administration suitable for indications such as inflammatory bowel disease and a variety of gut dysbioses. ChimAP has recently been shown to be efficacious in two rat models of acute kidney injury . A single iv dose of ChimAP (1000 U/Kg) was administered to Wistar rats within 30 minutes after ischemia- reperfusion (I-R) or LPS injection to induce AKI. ChimAP demonstrated pharmacological effect within the 3 hours of the experiment that included suppression of acute inflammation in the afflicted kidney and inhibition of tissue injury . Clinical trials using ChimAP have been initiated with the goal to treat patients with acute kidney injury (http://www.am-pharma.com/blog/2013/09/am-pharma-returns-to-clinic-with-phase-i-trial-of-new-recombinant-human-alkaline-phosphatase).
Protein structure modeling
The primary sequences of human IAP and ChimAP were submitted to the SWISS-MODEL server  to model their tertiary structures, based on homology to human placental alkaline phosphatase (1ZED). The resulting molecular structures were visualized and analyzed using Chimera v1.7  and Swiss-PdbViewer .
Expression plasmids containing secreted, FLAG epitope-tagged PLAP, IAP and TNAP were described previously , . ChimAP was constructed by substituting residues 360–430 of the mature IAP structure for the corresponding residues of mature PLAP. All four FLAG-tagged enzymes were transiently transfected into COS-1 cells by electroporation, then grown in DMEM medium for 24 h, as previously described , when the medium was replaced with serum-free Opti-MEM (Life Technologies, Grand Island, NY). Opti-MEM containing secreted proteins was collected 60 hours after transfection, then filtered through a 2-µm cellulose acetate filter and dialyzed against TBS containing 1 mM MgCl2 and 20 µM ZnCl2.
Western blot analysis
FLAG-tagged enzyme samples were denatured in 2% SDS and 0.025% β-mercaptoethanol and loaded on 8–16% acrylamide Tris-glycine gels (Invitrogen, Carlsbad, CA). Gels were transferred to Optitran nitrocellulose membranes  (Schleicher & Schuell Bioscience, Keene, NH), and blotted membranes were stained with Ponceau S to ensure efficiency of transfer. Washed membranes were blocked with SuperBlock reagent (Pierce Biotechnology, Rockford, IL) prior to incubation with mouse monoclonal anti-FLAG primary antibody (Sigma-Aldrich, St. Louis, MO), then peroxidase-labeled goat anti-mouse IgG (Calbiochem - Merck4Biosciences) as a secondary antibody.
To measure the relative catalytic activities of FLAG-tagged enzymes using different substrates, microtiter plates were coated with anti-FLAG M2 antibody (Sigma-Aldrich, St. Louis, MO) at 0.2–0.6 µg mL−1. These plates were incubated with saturating concentrations of FLAG-tagged PLAP, IAP or ChimAP for 3 h at room temperature, after which plates were washed with PBS, containing 0.008% Tween-80 and the relative activities for various substrates (p-nitrophenylphosphate (pNPP) and physiological substrates, see below) were compared for the M2-saturated enzymes. The activity of bound enzymes was measured as the absorbance at 405 nm (A405) as a function of time at 25°C, using pNPP (0.02–20 mM) as a substrate, at pH 9.8 in 1 M diethanolamine (DEA) buffer containing 1 mM MgCl2 and 20 µM ZnCl2, or at pH 7.4 in 50 mM Tris-HCl buffer, 100 mM NaCl, containing 1 mM MgCl2 and 20 µM ZnCl2, as indicated. Recordings for kinetic analysis were selected from those parts of the curve where A405 versus time was linear; initial rates were calculated over a period of up to 1 h, excluding the first 5 min. 1/v versus 1/[substrate] Lineweaver-Burk plots were constructed and linear regression was performed, calculating slopes (± SD) and intercepts (± SD), in Prism v3.0a (GraphPad Software) to determine Km values. Catalytic rate constants (kcat) were derived by comparison with the values measured for PLAP-FLAG, which was used as an internal standard with a known kcat for pNPP (460 s−1) at pH 9.8, at equal amounts of M2-saturated FLAG-enzymes.
Similarly, known concentrations of commercial recombinant human IAP (Sino Biological Inc., Beijing, China), human PLAP (Sigma-Aldrich, St. Louis, MO) and recombinant bovine intestinal alkaline phosphatase (Roche Diagnostics, Indianapolis, IN) were incubated with pNPP (0.1–10 mM) at pH 9.8, and Lineweaver-Burk plots were constructed, from which Km was determined. Numerical values for kcat at pH 9.8 were calculated by dividing the rate measured for 20 mM pNPP in 1 M diethanolamine buffer containing 1 mM MgCl2 and 20 µM ZnCl2 by the known enzyme concentration, using a molar extinction coefficient ε = 18,000 M−1 cm−1 for p-nitrophenol, at pH 9.8.
For the direct measurements of kcat at physiological pH, we used lipopolysaccharides (LPS) from Escherichia coli O111:B4 (Product number L 2630, Sigma, St. Louis, USA). This LPS preparation is in aggregated form and was dissolved as recommended in the manufacturer's data sheet. All other substrates, PPi, pyridoxal-5′-phosphate (PLP), ATP, ADP and AMP were also from Sigma-Aldrich (St. Louis, MO). Hydrolysis of the physiological substrates was measured at pH 7.4 in standard assay buffer (50 mM Tris-HCl buffer, 100 mM NaCl, 1 mM MgCl2 and 20 µM ZnCl2). The concentration of released phosphate was determined using Pi ColorLock Gold (Innova Biosciences) by measuring absorbance at 650 nm (A650). Standard curves constructed for increasing concentrations of phosphate were linear between 0–50 µM and all experiments were designed to fall within this range of hydrolyzed phosphate concentrations. Molar reaction rates, expressed as [Pi] s−1 were calculated for the indicated substrate concentration range and were fitted to a one-binding site model (GraphPad Prism) versus [substrate] to calculate Km (Lineweaver-Burk plots were not applied, because of lack of precision of reciprocal conversions at very low substrate concentrations). To compute kcat, the calculated rate [Pi] s−1 was divided by the known enzyme concentration. Because of the lower molar extinction coefficient for pNPP at pH 7.4, the hydrolysis of pNPP at pH 7.4 was analyzed using the Pi ColorLock Gold method.
The following substrate concentrations were used: [pNPP] = 250 µM, [ATP] = 500 µM, [ADP] = 500 µM, [AMP] = 500 µM, [PPi] = 5 mM for ChimAP and 2.5 mM for the other enzymes, [PLP] = 400 µM and [LPS] = 2.5 mg mL−1 for ChimAP and 1.25 mg mL−1 for the other enzymes. The soluble enzyme concentration was about 1 nM and incubation times ranged from 15–30 min, depending on the catalytic efficiency for each enzyme. To ensure steady-state conditions and to correct for non-specific substrate signals in the Pi ColorLock Gold method, an early reading (at 5 min) was subtracted from the later reading, and ΔA650 was measured on the corresponding Pi standard curve, constructed for each experiment separately. All experiments were carried out three to five times and the derived constants are reported as mean ± SD.
To measure the heat stability, enzymes were incubated at 65°C in 1 M DEA (pH 9.8) containing 1 mM MgCl2 and 20 µM ZnCl2. Samples were removed at different time points and placed on ice, then residual activity was measured as described above with 10 mM pNPP. Enzymes were also incubated in this buffer for 10 min at increasing temperatures (25–100°C) and residual activity was measured in the same manner. For experiments where the stability of enzymes was measured in the presence of a denaturing agent, assays were performed in standard assay buffer containing 3.8 M guanidine hydrochloride. The absorbance was recorded continuously in the presence of 20 mM pNPP for up to 4 h and slopes were calculated at different time points. Slopes were plotted semi-logarithmically versus time, to determine the half-life (t1/2) of activity loss during the exponential phase.
Inhibition of enzyme activity by L-Phe (0–50 mM) and L-homoArginine (0–50 mM) was measured in standard assay buffer, as previously described . The IC50 was calculated from plots of residual enzyme activity against inhibitor concentration, using Origin plotting software (OriginLab). The nature of L-Phe inhibition was investigated using double-reciprocal plots of v versus substrate concentration, at various inhibitor concentrations. Integrated competition studies were carried out in standard assay buffer by premixing 0.1 mM pNPP with ATP (0–10 mM), PPi (0–10 mM) or LPS (0–2 mg mL−1), before adding 200 µL of this mixture to 10 µL of enzyme preparation and measuring p-nitrophenol formation at pH 7.4.
Zn2+ removal and reconstitution
The rate of Zn2+ dissociation was studied by pre-diluting the enzyme stock 10–10,000-fold in 50 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, that had been pretreated with BT Chelex 100 (Biolabs), which is a resin that efficiently chelates divalent ions. To avoid rebinding of dissociated Zn2+, diluted enzyme was incubated with 250 µM EDTA for increasing time intervals (0–360 min), during which time samples were removed and AP activity was measured in Chelex-treated 0.1 mM pNPP in 50 mM Tris-HCl buffer, pH 7.4, 100 mM NaCl. To avoid competitive inactivation by EDTA , samples were diluted 20-fold, to reduce EDTA concentration to 12.5 µM. Alternatively enzyme solutions were incubated at room temperature with Chelex to 30% of the total volume. After the indicated times, demetalated enzymes were incubated with 50 mM Tris buffer pH 7.4, containing 100 mM NaCl, supplemented with increasing concentrations of Zn2+ (0–20 µM), and the activity was measured in 0.1 mM pNPP in the Zn2+-reconstituted buffer .
All quantitative measurements were carried out 3–5 times and calculated numbers are represented as the mean +/− SD. Likewise, figures were constructed using mean values ± SD, unless indicated differently, in which case single tracings are shown, representative of at least 3 experiments. Differences in inhibition by uncompetitive inhibitors and GndCl were statistically validated via an unpaired t-test and calculation of a two-tailed P-value. Differences in the inactivation rate of PLAP, IAP and ChimAP by GndCl or EDTA were statistically evaluated from the slope of linearized exponential plots of residual enzyme activity vs time, using GraphPad Prism.
¶ MFH and JLM are joint senior authors on this work. Conceived and designed the experiments: JLM MFH PC. Performed the experiments: TK-M CRS KCdSG MB. Analyzed the data: TK-M CRS KCdSG MB PC MFH JLM. Contributed reagents/materials/analysis tools: AvE. Wrote the paper: MFH JLM.
- 1. Millán JL, Narisawa S, Lemire I, Loisel TP, Boileau G, et al. (2008) Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res 23: 777–787. doi: 10.1359/jbmr.071213
- 2. Lukas M, Kelly RE, Kantorovich LN, Otero R, Xu W, et al. (2009) Adenine monolayers on the Au(111) surface: structure identification by scanning tunneling microscopy experiment and ab initio calculations. J Chem Phys 130: 024705. doi: 10.1063/1.3046690
- 3. Moss AK, Hamarneh SR, Mohamed MM, Ramasamy S, Yammine H, et al. (2013) Intestinal alkaline phosphatase inhibits the proinflammatory nucleotide uridine diphosphate. Am J Physiol Gastrointest Liver Physiol 304: G597–604. doi: 10.1152/ajpgi.00455.2012
- 4. Chen KT, Malo MS, Beasley-Topliffe LK, Poelstra K, Millán JL, et al. (2011) A role for intestinal alkaline phosphatase in the maintenance of local gut immunity. Dig Dis Sci 56: 1020–1027. doi: 10.1007/s10620-010-1396-x
- 5. Bates JM, Akerlund J, Mittge E, Guillemin K (2007) Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell Host Microbe 2: 371–382. doi: 10.1016/j.chom.2007.10.010
- 6. Malo MS, Alam SN, Mostafa G, Zeller SJ, Johnson PV, et al. (2010) Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut 59: 1476–1484. doi: 10.1136/gut.2010.211706
- 7. Heemskerk S, Masereeuw R, Moesker O, Bouw MP, van der Hoeven JG, et al.. (2009) Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med 37: : 417–423, e411.
- 8. Pickkers P, Heemskerk S, Schouten J, Laterre PF, Vincent JL, et al. (2012) Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care 16: R14. doi: 10.1186/cc11159
- 9. Peters E, van Elsas A, Heemskerk S, Jonk L, van der Hoeven J, et al. (2013) Alkaline phosphatase as a treatment of sepsis-associated acute kidney injury. J Pharmacol Exp Ther 344: 2–7. doi: 10.1124/jpet.112.198226
- 10. Millán JL (2006) Mammalian Alkaline Phosphatases: From Biology to Applications in Medicine and Biotechnology. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co.
- 11. Meyer JL (1984) Can biological calcification occur in the presence of pyrophosphate? Archives of Biochemistry and Biophysics 231: 1–8. doi: 10.1016/0003-9861(84)90356-4
- 12. Whyte MP (2012) Hypophosphatasia. In: Glorieux FH, Jueppner H, Pettifor J, editors.Pediatric Bone: Biology and Diseases.3rd ed.San Diego, CA: Academic Press. pp. 771–794.
- 13. Foster BL, Nagatomo KJ, Tso HW, Tran AB, Nociti FH Jr, et al. (2013) Tooth root dentin mineralization defects in a mouse model of hypophosphatasia. J Bone Miner Res 28: 271–282. doi: 10.1002/jbmr.1767
- 14. McKee MD, Nakano Y, Masica DL, Gray JJ, Lemire I, et al. (2011) Enzyme replacement therapy prevents dental defects in a model of hypophosphatasia. J Dent Res 90: 470–476. doi: 10.1177/0022034510393517
- 15. Yadav MC, de Oliveira RC, Foster BL, Fong H, Cory E, et al. (2012) Enzyme replacement prevents enamel defects in hypophosphatasia mice. J Bone Miner Res 27: 1722–1734. doi: 10.1002/jbmr.1619
- 16. Yadav MC, Lemire I, Leonard P, Boileau G, Blond L, et al. (2011) Dose response of bone-targeted enzyme replacement for murine hypophosphatasia. Bone 49: 250–256. doi: 10.1016/j.bone.2011.03.770
- 17. Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, et al. (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366: 904–913. doi: 10.1056/nejmoa1106173
- 18. Narisawa S, Huang L, Iwasaki A, Hasegawa H, Alpers DH, et al. (2003) Accelerated fat absorption in intestinal alkaline phosphatase knockout mice. Mol Cell Biol 23: 7525–7530. doi: 10.1128/mcb.23.21.7525-7530.2003
- 19. Nakano T, Inoue I, Koyama I, Kanazawa K, Nakamura K, et al. (2007) Disruption of the murine intestinal alkaline phosphatase gene Akp3 impairs lipid transcytosis and induces visceral fat accumulation and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 292: G1439–1449. doi: 10.1152/ajpgi.00331.2006
- 20. Goldberg RF, Austen WG Jr, Zhang X, Munene G, Mostafa G, et al. (2008) Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci USA 105: 3551–3556. doi: 10.1073/pnas.0712140105
- 21. Ramasamy S, Nguyen DD, Eston MA, Alam SN, Moss AK, et al. (2011) Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis. Inflamm Bowel Dis 17: 532–542. doi: 10.1002/ibd.21377
- 22. Kaliannan K, Hamarneh SR, Economopoulos KP, Nasrin Alam S, Moaven O, et al. (2013) Intestinal alkaline phosphatase prevents metabolic syndrome in mice. Proc Natl Acad Sci U S A 110: 7003–7008. doi: 10.1073/pnas.1220180110
- 23. Le Du M-H, Millán JL (2002) Structural evidence of functional divergence in human alkaline phosphatases. J Biol Chem 277: 49808–49814. doi: 10.1074/jbc.m207394200
- 24. Llinas P, Stura EA, Ménez A, Kiss Z, Stigbrand T, et al. (2005) Structural studies of human placental alkaline phosphatase in complex with functional ligands. J Mol Biol 350: 441–451. doi: 10.1016/j.jmb.2005.04.068
- 25. Stec B, Cheltsov A, Millán JL (2010) Refined structures of placental alkaline phosphatase show a consistent pattern of interactions at the peripheral site. Acta Crystallogr Sect F Struct Biol Cryst Commun 66: 866–870. doi: 10.1107/s1744309110019767
- 26. Kozlenkov A, Manes T, Hoylaerts MF, Millan JL (2002) Function assignment to conserved residues in mammalian alkaline phosphatases. J Biol Chem 277: 22992–22999. doi: 10.1074/jbc.m202298200
- 27. Bossi M, Hoylaerts MF, Millán JL (1993) Modifications in a flexible surface loop modulate the isozyme-specific properties of mammalian alkaline phosphatases. J Biol Chem 268: 25409–25416.
- 28. Hoylaerts MF, Millán JL (1991) Site-directed mutagenesis and epitope-mapped monoclonal antibodies define a catalytically important conformational difference between human placental and germ cell alkaline phosphatase. Eur J Biochem 202: 605–616. doi: 10.1111/j.1432-1033.1991.tb16414.x
- 29. Hoylaerts MF, Manes T, Millán JL (1997) Mammalian alkaline phosphatases are allosteric enzymes. J Biol Chem 272: 22781–22787. doi: 10.1074/jbc.272.36.22781
- 30. Le Du MH, Stigbrand T, Taussig MJ, Menez A, Stura EA (2001) Crystal structure of alkaline phosphatase from human placenta at 1.8 A resolution. Implication for a substrate specificity. J Biol Chem 276: 9158–9165. doi: 10.1074/jbc.m009250200
- 31. Kozlenkov A, Le Du M-H, Cuniasse P, Ny T, Hoylaerts MF, et al. (2004) Residues determining the binding specificity of uncompetitive inhibitors to tissue-nonspecific alkaline phosphatase. J Bone Miner Res 19: 1862–1872. doi: 10.1359/jbmr.040608
- 32. Manes T, Hoylaerts MF, Müller R, Lottspeich F, Hölke W, et al. (1998) Genetic complexity, structure, and characterization of highly active bovine intestinal alkaline phosphatases. J Biol Chem 273: 23353–23360. doi: 10.1074/jbc.273.36.23353
- 33. Bortolato M, Besson F, Roux B (1999) Role of metal ions on the secondary and quaternary structure of alkaline phosphatase from bovine intestinal mucosa. Proteins 37: 310–318. doi: 10.1002/(sici)1097-0134(19991101)37:2<310::aid-prot16>3.3.co;2-2
- 34. Hung HC, Chang GG (2001) Differentiation of the slow-binding mechanism for magnesium ion activation and zinc ion inhibition of human placental alkaline phosphatase. Protein Sci 10: 34–45. doi: 10.1110/ps.35201
- 35. Ciancaglini P, Yadav MC, Simão AM, Narisawa S, Pizauro JM, et al. (2010) Kinetic analysis of substrate utilization by native and TNAP-, NPP1-, or PHOSPHO1-deficient matrix vesicles. J Bone Miner Res 25: 716–723. doi: 10.1359/jbmr.091023
- 36. Lei W, Nguyen H, Brown N, Ni H, Kiffer-Moreira T, et al. (2013) Alkaline phosphatases contribute to uterine receptivity, implantation, decidualization and defense against bacterial endotoxins in hamsters. Reproduction 146: 419–432. doi: 10.1530/rep-13-0153
- 37. Bentala H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer DK, et al. (2002) Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 18: 561–566. doi: 10.1097/00024382-200212000-00013
- 38. Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, et al. (2002) Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A 99: 9445–9449. doi: 10.1073/pnas.142063399
- 39. Murshed M, Harmey D, Millán JL, McKee MD, Karsenty G (2005) Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 19: 1093–1104. doi: 10.1101/gad.1276205
- 40. Narisawa S, Wennberg C, Millán JL (2001) Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization. J Pathol 193: 125–133. doi: 10.1002/1096-9896(2000)9999:9999<::aid-path722>3.0.co;2-y
- 41. Waymire KG, Mahuren JD, Jaje JM, Guilarte TR, Coburn SP, et al. (1995) Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. Nat Genet 11: 45–51. doi: 10.1038/ng0995-45
- 42. Street SE, Kramer NJ, Walsh PL, Taylor-Blake B, Yadav MC, et al. (2013) Tissue-Nonspecific Alkaline Phosphatase Acts Redundantly with PAP and NT5E to Generate Adenosine in the Dorsal Spinal Cord. J Neurosci 33: 11314–11322. doi: 10.1523/jneurosci.0133-13.2013
- 43. Pettengill M, Robson S, Tresenriter M, Millan JL, Usheva A, et al. (2013) Soluble Ecto-5′-nucleotidase (5′-NT), Alkaline Phosphatase, and Adenosine Deaminase (ADA1) Activities in Neonatal Blood Favor Elevated Extracellular Adenosine. J Biol Chem 288: 27315–27326. doi: 10.1074/jbc.m113.484212
- 44. Verpooten GF, Nouwen EJ, Hoylaerts MF, Hendrix PG, de Broe ME (1989) Segment-specific localization of intestinal-type alkaline phosphatase in human kidney. Kidney Int 36: 617–625. doi: 10.1038/ki.1989.238
- 45. Ince C, Ergin B, Van Elsas A (2013) Recombinant Alkaline Phosphatase Modulates Inflammation and Injury in Two Rat Models of AKI. Am Soc Nephrol 24 : poster FR-PO066.
- 46. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T (2009) The SWISS-MODEL Repository and associated resources. Nucleic Acids Res 37: D387–392. doi: 10.1093/nar/gkn750
- 47. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25: 1605–1612. doi: 10.1002/jcc.20084
- 48. Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714–2723. doi: 10.1002/elps.1150181505
- 49. Narisawa S, Hoylaerts MF, Doctor KS, Fukuda MN, Alpers DH, et al. (2007) A novel phosphatase upregulated in Akp3 knockout mice. Am J Physiol Gastrointest Liver Physiol 293: G1068–1077. doi: 10.1152/ajpgi.00073.2007
- 50. Hoylaerts MF, Ding L, Narisawa S, Van Kerckhoven S, Millán JL (2006) Mammalian alkaline phosphatase catalysis requires active site structure stabilization via the N-terminal amino acid microenvironment. Biochemistry 45: 9756–9766. doi: 10.1021/bi052471+
- 51. Hoylaerts MF, Manes T, Millán JL (1992) Molecular mechanism of uncompetitive inhibition of human placental and germ-cell alkaline phosphatase. Biochem J 286 (Pt 1): 23–30.
- 52. Ciancaglini P, Pizauro JM, Leone FA (1997) Dependence of divalent metal ions on phosphotransferase activity of osseous plate alkaline phosphatase. J Inorg Biochem 66: 51–55. doi: 10.1016/s0162-0134(96)00159-6